Source comparison
MK-677 Dosage Comparison: Research Applications and Expected Outcomes
10mg daily +40–60 from baseline Initial tolerance assessment, mild anabolic support, subjects with low baseline IGF-1 Minimal appetite increase, rare glucose elevation Sustainable long-term (12+ months) Best starting point for titration. Adequate for 30% of su
This comparison does not assign a generated winner or score.
- 10mg daily
- +40–60 from baseline
- Initial tolerance assessment, mild anabolic support, subjects with low baseline IGF-1
- Minimal appetite increase, rare glucose elevation
- Sustainable long-term (12+ months)
- Best starting point for titration. Adequate for 30% of subjects without escalation
- 15mg daily
- +55–75 from baseline
- Moderate anabolic protocols, recovery enhancement, transition dose during titration
- Moderate appetite stimulation, occasional mild water retention
- Sustainable 6–12 months
- Sweet spot for subjects seeking benefits without metabolic disruption. Underutilized in most protocols
- 20mg daily
- +70–90 from baseline
- Standard research dose, body recomposition studies, aging populations
- Noticeable hunger increase, mild fasting glucose elevation (5–10mg/dL), frequent water retention
- 3–6 month cycles recommended
- Most evidence-backed dose. Produces 80% of maximum benefit with manageable side effects
- 25mg daily
- +85–105 from baseline
- Maximum anabolic protocols, clinical GH deficiency models, athletic performance research
- Significant appetite dysregulation, fasting glucose +10–15mg/dL, pronounced water retention, occasional lethargy
- 8–12 week cycles maximum
- Approaches plateau of IGF-1 response. Additional risk without proportional benefit for most subjects
- 30mg+ daily
- +90–110 from baseline
- Not recommended outside specific research contexts
- Severe hunger, insulin resistance risk, HbA1c elevation, sleep disruption
- Not advised for sustained use
- Exceeds dose-response curve inflection point. No published data supports routine use above 25mg